(Biostatistics and Bioinformatics Core) The research proposed in The MD Anderson Cancer Center Prostate Cancer SPORE encompasses a broad range of activities, including studies of cell lines and animal models and clinical trials. These studies will generate many different types of data, including clinical, epidemiological, biochemical, immunohistochemical, pharmacokinetic, genotypic, and immunologic data. The Biostatistics and Bioinformatics Core for the Prostate Cancer SPORE has been a comprehensive resource for the biostatistic and bioinformatic needs that arise within the SPORE. This resource has the flexibility to match personnel with the evolving needs of the SPORE projects. We are able to incorporate sound experimental design principles within each project to enhance the interpretability of the study results, carry out data analyses using appropriate statistical methodology, and contribute to the interpretation of results via written reports and frequent interaction with project investigators. We can match core personnel with the expertise required in a specific area of a SPORE project to efficiently meet the ongoing needs of the multiple components of the projects.
The specific aims of the Biostatistics and Bioinformatics Core are as follows. 1) Provide guidance in the design and conduct of clinical trials and other experiments (including high-dimensional genomic and proteomic studies) arising from the ongoing research of the SPORE. 2) Provide innovative and tailored statistical modeling, simulation techniques, and data analyses as needed for the main projects, developmental research and career development projects, and other cores to achieve their specific aims. 3) Ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted. 4) Provide guidance in the design and use of an information system to store appropriate data generated by all projects; develop integrated computational libraries and tools for producing documented, reproducible statistical and bioinformatic analyses; and support the use of these tools for analyses conducted by and on behalf of the projects.
(Biostatistics and Bioinformatics Core) Core 1 (Biostatistics and Bioinformatics) is a cross-cutting Prostate Cancer SPORE resource in which personnel will have crucial roles in planning, conducting, and analyzing translational and clinical prostate cancer research in the main projects, other cores, developmental projects, and career development award efforts. Core 1 personnel will play significant roles in designing the proposed experiments and trials and in planning the data analysis in conjunction with an integrated data management system.
|Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169|
|Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461|
|Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176|
|Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707|
|Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106|
|Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76|
|Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43|
|Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924|
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174|
|Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69|
Showing the most recent 10 out of 217 publications